NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--As disclosed and announced at its 2010 annual general meeting, Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes immunotherapy company, and the Science and Technology Directorate division of the Department of Homeland Security (DHS) plan to sign a CRADA (Collaborative Research And Development Agreement) in the next few days that will allow a pilot proof-of-concept cattle safety study to be conducted late this summer.
